Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)

A Twelve-Week, Double Masked, Parallel Group, Primary-Therapy Pilot Study of the Safety and Efficacy of Travoprost 0.004% Compared to Pilocarpine 1% in Patients With Chronic Angle-Closure Glaucoma

The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chronic angle-closure glaucoma (CACG).

Inclusion Criteria:

• Age ≥ 18 years
• Chronic Angle Closure Glaucoma (CACG)
• 21-35 millimeters mercury mean intraocular pressure on Eligibility visit day at 9 AM
• Peripheral iridotomy performed ≥ 1 Month prior to the Screening visit
• Anterior chamber angle in which the trabecular meshwork is not visible for ≥180 degrees in gonioscopy without indentation
• Peripheral anterior synechiae (PAS)

Exclusion Criteria:

• Traumatic damage of the anterior chamber angle
• History of ocular inflammation or surgery (except for iridotomy) ≤ 3 months
• Patients who cannot be safely discontinued from use of all ocular hypotensive medication(s) for 12 days to 14 weeks
• Visual Acuity ≥ 1.0
• Contact lenses wearer